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Abstract
20-hydroxyeicosatetraenoic acid (20-HETE) is the ω-hydroxylation product
of arachidonic acid catalyzed by CYP4A and 4F enzymes. 20-HETE is a
vasoactive eicosanoid of the microcirculation exhibiting effects on both vascular
smooth muscle cells (VSMC) and endothelial cells (EC). In VSMCs, 20-HETE’s
bioactions include the stimulation of contraction, migration, and growth. In ECs,
elevated 20-HETE is associated with reduced nitric oxide (NO) bioavailability,
increased angiotensin converting enzyme (ACE) expression, and the promotion
of inflammation. Recently in our laboratory, we identified GPR75 as a novel
target of 20-HETE that promotes changes in blood pressure and vascular
function. The aim of this study is to assess the consequences of VSMC-targeted
overexpression of Cyp4a12, the primary 20-HETE producing enzyme in mice, on
blood pressure, vascular function, and vascular remodeling. Moreover, we looked
to examine whether the administration of a 20-HETE receptor antagonist
reverses the vascular phenotype associated with elevations in 20-HETE.
Mice with VSMC-specific overexpression of Cyp4a12 (Myh11-4a12) and
their littermate controls (WT) were generated by crossbreeding Cyp4a12-flox
mice (gifted by Dr. Schunck) with Myh11-Cre mice. Myh11-4a12 were
administered AAA (10 mg.kg-1.day-1), a 20-HETE receptor antagonist, in the
drinking water (vehicle). At the end of the experiments (12 days), renal interlobar
arteries (RIA) and mesenteric arteries (MA) were harvested for the assessment
of 20-HETE levels by LC-MS/MS, and vascular contractility, vasodilation, and
remodeling using wire and pressure myography.
xii

The Myh11-4a12 mice showed higher Cyp4a levels in MA compared to
WT mice (6.5±0.71 vs 3.4±0.70; Cyp4a/β-actin p<0.05). Myh11-4a12 mice had
increased 20-HETE levels in the MA (3334±891 vs. 545±197 pg/mg protein;
p<0.05) and RIA (1859±376 vs 242±62 pg/mg protein; p<0.05), but, urine 20HETE levels were not different (117±9 vs. 93±2 pg/mL; p=0.18) when compared
to WT. Myh11-4a12 mice displayed higher SBP compared to WT mice (145±2
vs. 127±2 mmHg; p<0.05). Administration of AAA for 12 days normalized BP in
Myh11-4a12 mice (124±2 mmHg vs. 147±4 mmHg, p<0.01). RIA from vehicle
treated Myh11-4a12 mice displayed a higher media to lumen (M:L) ratio
(0.277±0.025 vs 0.163 ± 0.009; p<0.01) and cross sectional area (CSA)
(15114±1871 vs 10560±641 μm2; p<0.01) compared to WT mice on vehicle.
Moreover, RIA from Myh11-4a12 mice on AAA exhibit a lower M:L ratio
compared to Myh11-4a12 mice on vehicle (0.215 ± 0.013, p<0.05), but CSA was
not different (14268 ± 1259 μm2). Higher constrictor responsiveness to
phenylephrine (EC50: 1.63x10-7 ± 3.75x10-8 vs 5.00x10-7 ± 0.7.85x10-8 M,
p<0.0001) and an impaired relaxation response to acetylcholine (Maximum
response at 10-4 M: 65 ± 1 vs 83 ± 2 % relaxation, p<0.001) was observed in RIA
from Myh11-4a12 mice compared to WT. Treatment of Myh11-4a12 mice with
AAA diminished the constrictor responsiveness to phenylephrine (EC 50 of
4.22x10-7± 4.55x10-8 M, p<0.0001) and improved the relaxation in response to
acetylcholine (92 ± 2 % relaxation, p<0.001). Myh11-4a12 mice had elevated
phosphorylation of myosin light chain compared to WT mice (1.60 ± 0.23 vs 1.00
± 0.06, Ser19 p-MLC/total MLC fold change, p<0.05). Myh11-4a12 mice on AAA
xiii

exhibited a decrease in myosin light chain phosphorylation compared to Myh114a12 mice on vehicle (0.94 ± 0.11, Ser19 p-MLC/total MLC fold change, p<0.05).
Upstream of myosin light chain is Rho kinase (ROCK). Expression of ROCK1
was assessed in RIA and Myh11-4a12 mice had increased ROCK1 expression
compared to WT mice (1.60 ± 0.21 vs 1.00 ± 0.18, ROCK1/β-tubulin fold change,
p<0.05) but AAA was unable to significantly reduce the expression (1.48 ± 0.20,
ROCK1/β-tubulin fold change). Pressure myography was performed to assess
20-HETE receptor antagonism on ROCK activity. In RIA from WT mice, 20-HETE
administration promoted a greater myogenic response and both AAA and ROCK
inhibitor (Y-27632) inhibited the 20-HETE response in relation to the myogenic
tone.
The results of this study suggest that VSMC specific overproduction of
Cyp4a12 and 20-HETE promotes increase in blood pressure and changes in
vascular reactivity. 20-HETE receptor antagonism was capable of reversing the
vascular pathology in mice with elevated 20-HETE presumably through inhibition
of ROCK activity.
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Introduction and Background
Biosynthesis 20-HETE
20-HETE is the ω-hydroxylation product of arachidonic acid catalyzed by
cytochrome P450 enzymes (CYP4A/4F), with Cyp4a12 being the primary 20HETE synthetase in mice. 20-HETE can be measured in tissue and in biological
fluids. The vascular system is a primary site of 20-HETE production and it can be
found in conduit arteries such as the aorta (Costa et al., 2018; Soler et al., 2018),
and resistant arteries such as mesenteric arteries (Zhang et al., 2001), renal
microvessels (Croft et al., 2000) and cerebral microvessels (Gebremedhin et al.,
1998, 2000). Within each vessel type, 20-HETE is generated in the vascular
smooth muscle cells (VSMC) (Harder et al., 1994; Gebremedhin et al., 1998) and
endothelial cells (EC) (Zhu et al., 2002; Chen et al., 2016; Joseph et al., 2017).
Circulating cells, such as endothelial progenitor cells, platelets, and myeloid cells,
can also generate 20-HETE (Rosolowsky et al., 1996; Christmas et al., 2001;
Wang et al., 2006; Tsai et al., 2011; Chen et al., 2014). The kidney tubules is
another site of 20-HETE production where it can be measured within the tissue
and contribute to the amount present in the urine (Gilani et al., 2020). Proximal
tubules are the predominate sources of 20-HETE in the kidney tubules, with
some production occurring in the thick ascending loop of henle (TALH), distal
convoluted tubule and the collecting tubules (Carroll, M. A., Sala, A., Dunn, C.E.,
McGiff, J.C., 1991; Omata et al., 1992). Heart, brain, lung and adipose tissue are
more examples of tissues that can produce 20-HETE (Zhu et al., 2002; Chuang
et al., 2004; Joseph et al., 2017; Gilani et al., 2018, 2021).
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Several factors can play a role in either the increase or decrease
production of 20-HETE. Androgens are well known for inducing Cyp4a
expression and their administration has been established as a model for global
overexpression of 20-HETE in mice and rats (Holla et al., 2001; CC Wu et al.,
2013). PPAR𝛄 agonists, such a Clofibrate, and parathyroid hormone can
increase Cyp4 activity (Roman et al., 1993; Ribeiro et al., 1994; Silverstein et al.,
1998). Angiotensin II, norepinephrine and endothelin-1 all facilitate increase in
20-HETE by promoting increases in intracellular calcium which is necessary for
cytosolic phospholipase A2 activity and arachidonic acid release from
phospholipids (Muthalif et al., 1996; Hercule and Oyekan, 2000; Parmentier et
al., 2001; Tsai et al., 2011). Factors such as carbon monoxide or nitric oxide
(NO) decrease 20-HETE production by binding to the heme moiety of Cyp4a
enzyme to prevent its formation (Wang et al., 2003; Kaide et al., 2004).
Several cytochrome P450 enzymes have been shown to be involved in
the production of 20-HETE across rodents and humans. In mice, Cyp4a10,
Cyp4a12, and Cyp4a14 have some capacity to produce 20-HETE, with Cyp4a12
having the greatest capacity (Capdevila and Falck, 2000; Roman, 2002; Muller et
al., 2007). The 20-HETE-producing enzymes in rats include Cyp4a1, Cyp4a2 and
Cyp4a3 (Nguyen et al., 1999; Hardwick, 2008). The main 20-HETE-producing
enzymes in humans are CYP4A11 and CYP4F2 (Powell et al., 1998; Lasker et
al., 2000).
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20-HETE effects on the vasculature
As indicated above, the vasculature is a significant source of 20-HETE
production and a prime target of its actions. 20-HETE is a vasoactive lipid
mediator affecting vascular tone and inflammation through actions on the
vascular endothelium and the smooth muscle.

Actions on vascular endothelium
The vascular endothelium is a single layer of cells containing many factors
that can diffuse to the smooth muscle to allow for changes in tension of vessels.
20-HETE overproduction has been shown to act in the endothelium to promote
constriction. These actions include: 1) reduced NO bioavailability, 2) actions on
renin-angiotensin-system, and 3) activation of endothelium inflammation
processes.
NO is produced in the endothelium, by endothelial-specific nitric oxide
synthase (eNOS), which is expelled to the VSMCs to exert its effect. 20-HETE
can act on different parts of this signaling pathway to lower NO bioavailability. 20HETE has a direct inhibitory effect on eNOS. Both in vitro and in vivo, 20-HETE
has been shown to inhibit activation of eNOS by preventing phosphorylation at
serine 1179 (Cheng et al., 2008; Inoue et al., 2009). Furthermore, 20-HETE has
been shown to cause eNOS uncoupling with HSP90 via NF-κB-IKK signaling
pathway (Cheng et al., 2010). 20-HETE also has indirect mechanisms which
lower the bioavailability of NO. 20-HETE has been shown to increase superoxide
production through NADPH oxidase-dependent and -independent mechanisms
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(Guo et al., 2007; Medhora et al., 2008). The increase in superoxide shunts NO
to produce peroxynitrite which prevents it from migrating to the VSMCs to cause
dilation (Medhora et al., 2008).
20-HETE has been shown to increase the expression and activity of
angiotensin converting enzyme (ACE). Induction of 20-HETE production in vivo
and in vitro has been shown to increase endothelial ACE expression via NF-kBIKK pathway (Cheng et al., 2012; Garcia et al., 2016). Increases in ACE
expression were accompanied by increases in angiotensin II levels which can act
on its own receptor to cause changes in vessel function (Sodhi et al., 2010).
Vascular inflammation is another effect of 20-HETE in the endothelium.
Reports have shown that 20-HETE can increase inflammatory markers such as
IL-6 and IL-8 and adhesion molecules such as ICAM (Guo et al., 2007; Ishizuka
et al., 2008). 20-HETE has been shown to increase NF-κB and MAPK, which
facilitate the production of inflammatory markers (Guo et al., 2007; Ishizuka et al.,
2008). The inflammatory state of the vessels can be reversed with administration
of 20-HETE synthase inhibitor.
Angiogenesis is the process of making new blood vessels from preexisting
vessels. This process requires the coordinated action of the endothelium to
branch out from the vessel, migrate away from the branch point and form a tube
structure. 20-HETE in vitro has been shown to increase EC proliferation as a
result of both increases in VEGF and HIF-1α (Guo et al., 2007, 2009). These
actions relied on an increased oxidative environment which resulted in the
activation of the NF-κB pathway. Furthermore, 20-HETE in vivo has been shown

4

to upregulate angiogenesis by promoting endothelial progenitor cell homing and
adhesion to the EC (Chen et al., 2014, 2016).

Actions on vascular smooth muscle
The VSMC is the contractile unit within the vasculature. It is located in the
tunica media adjacent to ECs. Contraction caused by VSMCs play a role in
maintaining blood flow to tissues. 20-HETE has been documented to change the
VSMC phenotype by either: 1) increased sensitivity to contractile stimuli and 2)
increased vessel wall thickness. These changes in VSMC physiology ultimately
reduces blood flow, reduce compliance and increases in blood pressure.
VSMCs are responsible for causing contraction to redirect blood flow to
tissue with higher metabolic demand. It is important for VSMC to be sensitive to
specific stimuli that can promote changes in lumen diameter so tissues can
receive a consistent blood flow. Autoregulation is an intrinsic property of a vessel
where blood flow is maintained despite changes in pressure in the system.
Autoregulation relies on the ability of the vessel to contract when it senses
increase transluminal pressure, defined as the myogenic response (Davis et al.,
1992). 20-HETE has been documented, in cerebral and renal circulation, to
promote contraction which shift the autoregulation curve to the right so vessels
maintain a constant flow at higher pressures (Zou et al., 1994; Gebremedhin et
al., 2000). Inhibition of 20-HETE synthesis has been shown to cause dilation and
prevent the vessel’s autoregulatory ability.
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20-HETE has been shown to promote contraction in VSMCs by 1)
increasing intracellular calcium and 2) activating Rho kinase. Calcium signaling is
important because it is the initial step to cause VSMCs contraction. Calcium
enters the VSMC through the L-type calcium channel which increase intracellular
calcium levels. The increase in intracellular calcium activates calmodulin which
then activates myosin light chain kinase (Tansey et al., 1994; Raina et al., 2009).
Myosin light chain kinase phosphorylates the myosin light chain which is the
necessary signal in order to initiate excitation-contraction in the VSMCs (Driska
et al., 1981). The mechanisms by which 20-HETE affects intracellular calcium
levels are through inhibition of the large-conductance Ca2+-activated K+-channel
(BKCa2+) (Zou et al., 1996; Lauterbach et al., 2002; Fan et al., 2013; Toth et al.,
2013) and activation of L-type calcium channels (Gebremedhin et al., 1998).
Mechanisms exist within the VSMC to terminate signaling for contraction.
Myosin light chain phosphatase is the protein within the VSMC that can remove
the phosphate group off of myosin light chain and inhibit contraction (Wang et al.,
2009). The activity of myosin phosphatase is regulated by Rho-kinase (ROCK).
The activation of ROCK is initiated by GPCR-mediated mechanisms to activate
Rho-GTP which removes the inhibitory subunit on ROCK (Swärd et al., 2003).
20-HETE has been reported to increase the activity of ROCK and increase
myosin light chain phosphorylation (Randriamboavonjy et al., 2003). The
inhibition of mechanisms to remove phosphate from myosin light chain sensitizes
VSMCs to other constrictor stimuli.
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The vascular wall is dynamic in that it can respond to external cues to
change its architecture. In the normal state, the vessel is quiescent, but in the
presence of certain stimuli, the vessel can undergo processes which allow it to
thicken to compensate for the elevated pressure (Li et al., 1994; Garcia, et al.,
(2015b)). The consequences of remodeling in the vessels include decreases in
compliance, reduced blood flow and ultimately even further increase in blood
pressure. 20-HETE promotes changes in vascular wall remodeling without
contribution to sympathetic nerve activation (Ding et al., 2013), as well as
increase in ACE (Garcia, et al., (2015b)). Thus, 20-HETE displays its own
signaling mechanism to promote thickening of the vascular wall. There are
several signaling mechanisms which contribute to the mitogenic effect of 20HETE. First, 20-HETE causes VSMC migration by activation of the MAP-kinase
and PI3K/Akt signaling pathways (D Stec et al., 2007). Proliferation is also
increased with 20-HETE. In vitro experiments with norepinephrine stimulation
suggests that 20-HETE promotes proliferation via MAP-kinase signaling (Uddin
et al., 1998; Kalyankrishna and Malik, 2003). 20-HETE has also been shown to
cause proliferation in vivo. In an experiment by Orozco and colleagues (2013),
they used a balloon injury model to promote carotid artery thickening which was
prevented by administration of Cyp4a inhibitors (Orozco et al., 2013).
Another contributor to the changes in vascular wall remodeling is through
changes in the architecture of the extracellular matrix (ECM). The ECM is
comprised of structural proteins that give the vessels its ability to withstand
changes in wall tension. The actions of 20-HETE within the ECM includes
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increased collagen IV deposition (Ding et al., 2013) and elastin degradation
(Soler et al., 2018). 20-HETE can increase reactive oxygen species in VSMCs
(Lakhkar et al., 2016) which can act as a second messenger for the increased
production of MMP12 that degrades elastin in conduit arteries (Soler et al.,
2018). These actions contribute to the reduction in compliances that result in
elevated blood pressure.

Other actions of 20-HETE
The actions of 20-HETE are not limited to maintenance of vascular tone
within the central circulation. 20-HETE has numerous actions within structures of
the kidney that result in changes in plasma osmolality. In renal preglomerular
vessels, 20-HETE has been shown to sensitize vessels to phenylephrine-induced
constriction and impaired relaxation after acetylcholine administration (CC Wu et
al., 2013). Impairment in preglomerular microvessel activity resulted in reductions
in glomerular filtration rate (Pandey et al., 2017) and an increase in proteinuria
(Inoue et al., 2009). These changes resulted in an elevation in plasma osmolality
and, ultimately, increases in blood volume. 20-HETE is produced and has actions
within the kidney tubules (Omata et al., 1992; Lin et al., 1995). 20-HETE has
been shown to act on different transporters in the nephron and, depending on the
transporter, has a different effect on salt excretion. 20-HETE pro-natriuretic effect
includes inhibition of Na+-K+-ATPase (Schwartzman et al., 1985; Nowicki et al.,
1997) in the proximal tubule and sodium-potassium-chloride cotransporter
(NKCC2) in the thick ascending limb (Amlal et al., 1996, 1998). Furthermore, 20-
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HETE also can increase the activity of the sodium chloride transporter resulting
in an anti-natriuretic effect (Savas et al., 2016; Gilani et al., 2020).
20-HETE also has actions to promote increases in body weight gain and
changes in insulin signaling. In human subjects, correlations have been shown
between elevated 20-HETE in the urine and increased BMI. Mouse models of
Cyp4a12 overexpression have also shown that elevated 20-HETE promotes
increases in body weight and insulin resistance when on a high-fat diet (Gilani et
al., 2018, 2021). These actions of global expression of Cyp4a12 were reversed
when mice were administered 20-SOLA (a 20-HETE antagonist) (Gilani et al.,
2018, 2021). The consequence of 20-HETE overproduction after a high-fat diet
shows changes in insulin signaling and hyperglycemia. One report shows that
overexpression of CYP4F2 promotes hyperglycemia on a normal diet (Lai et al.,
2012). Hyperglycemia can be contributed to changes in insulin signaling. Reports
have shown that 20-HETE can affect activation of the insulin receptor and/or the
ability of IRS-1 to dock on the insulin receptor (Li et al., 2014; Gilani et al., 2018,
2021). One report shows that 20-HETE can inhibit glucose-mediated insulin
secretion through the FFAR1 receptor (Tunaru et al., 2018).

The 20-HETE receptor, GPR75
The cellular mechanisms underlying the bioactions of 20-HETE have been
extensively studied; however, what remains to be elucidated is the up-stream
factors that result in the initiation of 20-HETE’s signaling cascade. The first report
to demonstrate 20-HETE’s proximal signaling was published by Garcia and
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colleagues (2017). They were the first to show that 20-HETE binds to a cell
surface receptor, namely GPR75, and to report the proximal signaling
mechanism through which 20-HETE causes hypertension and vascular
dysfunction (Garcia et al., 2017).
GPR75 is a 7-transmembrane G-protein coupled receptor (GPCR) that is
classified as an orphan receptor (Garcia et al., 2017). The gene for this receptor
was identified on the 2p16 chromosome and translation of this gene results in a
540 amino acid GPCR with a molecular weight of 59 kDa (Tarttelin et al., 1999).
A unique feature of this receptor is its c-terminal tail that is 169 amino acids in
length, which is longer than most GPCRs (Pease, 2006). The extended tail
allows for docking of proteins to initiate complex signaling cascades. In several
different cell models, GPR75 has been shown to complex with Gq, hic-5, c-Src
and GIT-1 (Ignatov et al., 2006; Garcia et al., 2017).
The expression of GPR75 can be found in the retinal pigmented
epithelium, brain and heart (Tarttelin et al., 1999; Dedoni et al., 2018; GonzalezFernandez et al., 2020). GPR75 expression is also detected in the vascular
endothelium and smooth muscle (Garcia et al., 2017; Gonzalez-Fernandez et al.,
2020), pancreatic islets (Liu et al., 2013) and prostatic cancer cells (Cárdenas et
al., 2020). Within these cell types, it has been shown that activation of GPR75,
mediated by Gq, increases intracellular calcium which then activates downstream
signaling including phospho-ERK1/2 (Ignatov et al., 2006; Garcia et al., 2017;
Dedoni et al., 2018; Cárdenas et al., 2020). Garcia et. al. (2017), demonstrated
that in VSMCs 20-HETE-GPR75 pairing results in a PKC- and c-Src-mediated
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phosphorylation of BKCa2+ channels leading to their inactivation (Garcia et al.,
2017).
The effects of 20-HETE on the cardiovascular system through its binding
to GPR75 is a new area of research. There is evidence that individuals with a
permutation of the 2p chromosome (the site of GPR75 gene) are more likely to
be non-responders to current hypertensive therapies (Padmanabhan et al.,
2006). Thus, exploring the effects of GPR75 on blood pressure can be useful.
Garcia et. al. (2017) showed that mice with overexpression of Cyp4a12 were
hypertensive and knocking down GPR75 with shRNA normalized blood pressure
(Garcia et al., 2017). Furthermore, pharmacological antagonism of the 20-HETEGPR75 pairing has been shown to blunt 20-HETE-dependent actions in the
cardiovascular system as well as in disease models (Pandey et al., 2017; Gilani
et al., 2018, 2021; Soler et al., 2018). In a report by Sedlákova et. al. (2018), they
generated a rat model with elevated 20-HETE and angiotensin II that
dramatically increased the blood pressure. They administered AAA (a novel 20HETE receptor antagonist) which was able to lower the blood pressure of these
rats (Sedláková et al., 2018). In another report, AAA was shown to blunt the
effects of 20-HETE on the metastatic features in a prostate cancer cell line
(Cárdenas et al., 2020). Thus, pharmacological antagonism may be a therapeutic
strategy for the treatment of 20-HETE-related diseases.
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20-HETE and hypertension
The link between 20-HETE and hypertension has been well established
across numerous animal models. The use of animal models has been vital in
understanding the actions of 20-HETE in vivo. Animal models have shown the
consequences of elevated 20-HETE levels on vascular and renal function. Some
examples of animal models include: 1) Cyp4a12-tg, 2) DHT-pellet-treated mice,
3) Cyp4a14-/-, 4) spontaneously hypertensive rats, and 5) Dahl salt-sensitive
hypertensive rats.
The Cyp4a12-tg mouse has elevated 20-HETE production in the presence
of doxycycline (CC Wu et al., 2013). This mouse was engineered to have
Cyp4a12 expression controlled by the tetracycline inducible promoter. This is
advantageous in experiments where control of 20-HETE production is necessary.
Administration of doxycycline (DOX) in these mice resulted in changes in blood
pressure and vascular reactivity that are dependent on 20-HETE (CC Wu et al.,
2013; Ding et al., 2013; Gilani et al., 2021).
Androgens are a known inducer of Cyp4a expression and 20-HETE. Two
animal models of androgen-inducible 20-HETE include the DHT-pellet-treated
mouse and the Cyp4a14-/- mouse. DHT-pellets are implanted subcutaneously in
the mouse which allows for global overproduction of Cyp4a12 and 20-HETE that
can be observed in male and female mice (Singh et al., 2007; CC Wu et al.,
2013; Garcia et al., (2015a)). The Cyp4a14-/- mouse also resulted in increased
Cyp4a12 and 20-HETE. The deletion of the Cyp4a14 gene promotes androgendriven Cyp4a12 expression that is only observable in male mice (CC Wu et al.,
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2013; Ding et al., 2013; Pandey et al., 2017). Both these experimental models
are associated with elevation in blood pressure, altered vascular function and
kidney function.
The Tie2-CYP4F2-Tr mouse is a genetically engineered mouse that
displays overexpression of the human CYP4F2 gene specifically in EC (Cheng et
al., 2014). These mice have elevated 20-HETE in EC of tissues including kidney,
lung, liver, heart and aorta. The Tie2-CYP4F2-Tr displayed changes in the
angiogenic phenotype but do not have any differences in blood pressure
compared to wild type mice (Cheng et al., 2014).
The spontaneously hypertensive rat (SHR) is documented to have
elevated Cyp4a1, Cyp4a2, and Cyp4a3 levels which all contribute to the
elevation of 20-HETE (Sacerdoti et al., 1989; Roman, 2002; Dunn et al., 2008).
This rat model has been documented to have increases in blood pressure,
vascular reactivity and changes in cerebral and renal blood flow (Zhang et al.,
2001; Dunn et al., 2008). The changes in cerebral circulation were associated
with cerebral infarcts (Dunn et al., 2008).
The Dahl salt-sensitive hypertensive rat is an example of an animal model
where lower 20-HETE levels result in elevated blood pressure. In the medullary
area of the kidney, Cyp4a expression was reduced (Stec et al., 1996).
Reductions in Cyp4a and 20-HETE were associated with changes in transluminal
voltage due to uninhibited activity of the NKCC2 cotransporter (Roman and
Kaldunski, 1991; Ito and Roman, 1999). This increased salt and fluid
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reabsorption which contribute to the elevation in blood pressure (J Wu et al.,
2013).
Hypertension is defined as the chronic elevation of blood pressure,
>130/80mmhg (CDC, 2020). In the United States, nearly half of adults fit into this
definition with men, African Americans and/or Hispanics having a greater risk of
developing hypertension (CDC, 2020). Individuals with elevated blood pressure
are at a greater risk of coronary heart disease, stroke, and renal failure
(Gosmanova et al., 2016). Current therapies, such as ACE inhibitions, diuretics,
beta-blockers, and calcium channel blockers target their respective signaling
mechanism to reduce blood pressure. However, approximately one-third of the
population do not see a successful outcome from using hypertensive medications
(Cushman et al., 2002). Thus, new therapies are in need to improve the clinical
outcome within these patients.
CYPs are well known to have genetic variations that are correlated with
increasing blood pressure in humans (Rocic and Schwartzman, 2018). Genetic
polymorphisms have been shown to change the catalytic activity of these
enzymes. For example, the T8590C SNP for CYP4A11 and the V433M in
CYP4F2 have been shown to be associated with hypertension (DE Stec et al.,
2007; Laffer et al., 2008; Ward et al., 2008; Huang et al., 2020). Changes in
catalytic activity of these enzymes may affect 20-HETE levels which drives the
changes in blood pressure. 20-HETE has been shown to correlate with certain
factors in hypertensive patients. 20-HETE has been shown to positively correlate
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with blood pressure in patients with salt-sensitive hypertension (Laffer et al.,
2003), and negatively correlate with flow-dependent dilation (Ward et al., 2004).
The effects of 20-HETE on blood pressure and sodium handling are
complex. On one hand, it inhibits ion transport along the nephron leading to
natriuresis thus contributing to anti-hypertensive mechanisms. For example, Dahl
salt-sensitive hypertensive rats are known to have decreased Cyp4a expression
and 20-HETE production which is associated with higher blood pressure (Stec et
al., 1996). 20-HETE in the kidney tubule has been shown to inhibit the NKCC2
co-transporter, which is occurring at a lower frequency in the Dahl salt-sensitive
rat (Escalante et al., 1991, 1994; Ito and Roman, 1999). On the other hand,
global overexpression models of 20-HETE, including 5-dihydrotestosterone
treated mice (Ding et al., 2013), Cyp4a12 transgenic mice (Garcia, et al.,
(2015b)), and the Cyp4a14-/--knock out mouse (Holla et al., 2001; CC Wu et al.,
2013) all have been shown to promote vasoconstriction and increases in
peripheral vascular resistance and blood pressure due to systemic elevations of
20-HETE.
The proposed studies are aimed at identifying the cellular mechanism
(GPR75-mediated) by which 20-HETE affects VSMC contractility and
determining the role of VSMC-derived 20-HETE in the control of blood pressure.
The influence of 20-HETE in the regulation of blood pressure makes it an
attractive target for therapeutic intervention. The discovery of GPR75 as the 20HETE receptor provides a specific therapeutic site to target 20-HETE bioactions.
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Hypothesis
Smooth muscle-specific overexpression of Cyp4a12-20-HETE-synthase
results in hypertension and impaired vascular function that is 20-HETEdependent
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Specific Aims
Aim 1: To determine if smooth muscle-specific overexpression of Cyp4a1220-HETE synthase (Myh11-4a12) causes hypertension and vascular
dysfunction
a) Establish transgenic mice with smooth muscle-specific overexpression
of the Cyp4a12-20-HETE synthase (Myh11-4a12).
b) Characterize the phenotype of the Myh11-4a12 with respect to blood
pressure and vascular function including contractility, vasodilatory
response and remodeling.

Aim 2: To determine if the hypertension and vascular pathology in Myh114a12 mice are 20-HETE-dependent
a) Use a 20-HETE receptor antagonist to determine whether the
hypertensive and vascular phenotype of the Myh11-4a12 mice are 20HETE dependent

Aim 3: To explore cellular mechanisms underlying the changes in vessel
reactivity of arteries from mice with smooth muscle-specific
overexpression of Cyp4a12
a) Assess expression of known 20-HETE targets (e.g., eNOS, ACE, Rhokinase, MLC) in vascular beds including renal microvessels and
mesenteric arteries by qRT-PCR and Western blot.
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b) Examine whether activation of the Rho-kinase underlies the contractile
phenotype of arteries from Myh11-4a12 mice using pressure
myography, 20-HETE receptor antagonists and a Rho-kinase inhibitor.
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Materials and Methods

Animals: Mice with VSMC-specific overexpression of Cyp4a12 were generated
by crossing mice with cre-recombinase expression driven by the VSMC-specific
myosin heavy chain promoter (Myh11-Cre+/-) and Cyp4a12-flox mice (Cyp4a12flox+/+). Cyp4a12-flox+/+ mice contain loxP sites flanking a regulatory region of the
Cyp4a12 promoter. In the presences of cre-recombinase, the regulatory region is
removed and unregulated Cyp4a12 production can occur. Pups generated were
divided into wild type (WT: Myh11-4a12-Cre-/--Cyp4a12-flox+/wt) or positive mice
(Myh11-4a12: Myh11-Cre+/--Cyp4a12-flox+/wt). All mice were housed in static
cages and fed standard chow. Experiments were conducted on mice between
the ages of 2-4 months. A novel water-soluble 20-HETE receptor antagonist, Ndisodium succinate-20-hydroxyeicosa-6(Z),15(Z)-diencarboxamide (AAA), was
used to assess the relevance of 20-HETE in the phenotype of these mice. Mice
were divided into three groups: 1) Wild-type – vehicle; 2) Myh11-4a12 – vehicle;
and 3) Myh11-4a12 – AAA treatment. Baseline SBP was measured before
administration of AAA. Mice were administered either vehicle (tap water) or AAA
at a dose of 10mg.kg-1.day-1 in drinking water. Systolic blood pressure was
measured on days 0, 4, 8, and 12. After the last blood pressure measurement,
mice were sacrificed and tissues were collected for physiological and
biochemical analysis.

Blood Pressure Measurements: Systolic blood pressure (SBP) was measured
using CODA non-invasive tail-cuff method (Kent Scientific, Torrington, CT). The
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CODA tail-cuff system utilizes volume-pressure recording (VPR) technology to
measure the expansion of the mouse’s tail due to the return of blood flow after
occlusion. All cuffs and bladders were checked for patency before measurements
were taken. A warming plate was set to 32-35o Celsius to maintain body
temperature during the measurement. The CODA software was set to have a
deflation time of 20 seconds and allowed measurements of ≥ 15μL. Mice
underwent 30 inflation-deflation cycles. The first 5 cycles were dedicated for
acclimation and was not used in blood pressure determination. The last 25 cycles
were used for blood pressure measurements. All cycles were carefully examined
and cycles were removed if artifacts were identified in the measurement. All mice
were allowed 5-7 days to undergo the tail-cuff procedure without collecting data.
Baseline measurements per mouse were obtained by taking the average SBP on
three separate days. Blood pressure measurements on AAA were measured on
days 0, 4, 8, and 12. The CODA system is able to measure SBP within ±10% of
actual value.

Wired Myography: Phenylephrine-induced contraction, as well as acetylcholine
and SNP induced relaxation were performed on renal interlobar arteries (RIA).
Kidneys were taken out of mice and were carefully dissected in a dish containing
Kreb’s buffer. Isolated vessels were mounted onto wires in a chamber of a
multivessel myograph. Before conducting experiments, vessels were allowed to
sit in a bath containing Kreb’s buffer, maintained at 37oC, and constantly being
bubbled with 95/5% O2/CO2 for 30-60 minutes. All vessels were set to an internal
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circumference that is 90% of what the circumference would be at 100mmHg.
Isometric tension was measured throughout the experiment. Cumulative
phenylephrine dose-response experiments were performed. Phenylephrine was
administered at half-dose intervals from (10-9-10-4 M) directly into the tissue bath.
Tension was represented as a percentage of the maximal response at 10-4 M
phenylephrine. Percent maximal response % = [(tension at a dose Phe/(tension
10-4 M Phe - baseline tension))*100]. Acetylcholine or sodium nitroprusside
(SNP) relaxation experiments were also performed. Before acetylcholine or SNP
administration, precontraction was achieved by administering phenylephrine (10 -6
M) to the vessel bath. Acetylcholine (10-8-10-4 M) or SNP (10-9-10-5 M) was
administered in a cumulative dose-dependent fashion after phenylephrine
induced precontraction. The percent relaxation was calculated by subtracting the
tension after a dose of acetylcholine or SNP from the tension generated from 10-6
M phenylephrine, divided by the difference between the baseline tension and 10-6
M phenylephrine. Percent relaxation % = [(tension at a dose of Ach or SNP [M] tension at [10-6 M] Phe)/ (tension at [10-6 M] Phe - baseline tension)*100].

Pressure Myography: Renal interlobar arteries were dissected in the same
manner as for wired myography experiments. Living Systems Instrumentations
(St. Albans City, VT) pressure myograph was used to induce pressures within the
lumen of the vessel. The distances of the inner and outer diameters were
measured using video edge detection. One end of the renal interlobar artery was
mounted onto a glass canula and the other side was ligated closed. The vessel
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was allowed to equilibrate for one hour at 37oC in Kreb’s buffer bubbled with
95/5% O2/CO2. For measurements of vascular wall thickness, internal pressures
of 100mmHg were induced on normotensive vessels and 140mmHg on
hypertensive vessels. Measurements of outer diameter (OD) and inner diameter
(ID) under passive conditions were used to calculate media thickness [(OD ID)/2], media:lumen ratio [(OD - ID)/ID], and medial cross-sectional area [CSA
(π/4) x (OD2 - ID2)]. For measurements of myogenic response, only WT vessels
were used. Each vessel underwent 5 consecutive treatments in the following
order: 1) vehicle only (100% ethanol), 2) 20-HETE (10 μM), 3) 20-HETE + AAA
(10 μM), 4) 20-HETE + Rho-kinase inhibitor (Y-27632, 10 μM), and 5) 20-HETE
+ AAA + Rho-kinase inhibitor. Passive stretch of vessels was also assessed
immediately after the treatments by measuring the internal diameter of the vessel
in a calcium-free Kreb’s solution. Vessels were subjected to pressures of 0, 20,
40, 60, 80 and 100 mmHg and ID was measured at each pressure. The Absolute
and normalized ID were determined after experiments were concluded. The
normalized ID was represented as a percentage and calculated as follows:
normalized ID = (absolute ID/passive ID)*100.

Sodium Excretion Studies: On the last day of AAA treatment, mice were
individually housed in metabolic cages to collect urine (Hatteras instruments).
Twenty-four-hour urine collection was taken and urine samples were stored at 80oC until time to measure urinary sodium. Water consumption and urine volume
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were measured to assess fluid balance. Urinary sodium measurements were
performed using flame photometry.

Western blots: Mesenteric arteries were taken out and carefully dissected in icecold MOPS buffer to remove fat tissue. Vessels were flash-frozen in liquid
nitrogen and stored at -80oC. Tissues were lysed by crushing vessels in liquid
nitrogen followed by homogenization in RIPA buffer containing protease and
phosphatase inhibitor. Lysates were allowed to sit on ice for 15 minutes before
centrifugation. Lysates were spun at 10,000 RPM for 15 minutes at 4 oC and
supernatant was collected for western blot experiments. Protein estimation was
performed using BCA assay. Equal amounts of protein were loaded onto a 10%polyacrylamide gel and ran at 125V. Proteins were transferred onto a PVDF
membrane using methanol-glycine-tris-base transfer buffer. After transfer,
membranes were blocked in TBS buffer containing 1% bovine serum albumin for
1 hour. Cyp4a (1:1000 – Santa Cruz – cat#: sc-271983), Myh11 (1:1000 –
Abcam – cat#: ab125884), ROCK1 (1:1000 – Sigma – cat#: HPA007567), Serine
1177 p-eNOS (1:100 – cell signaling technology – cat#: 9571S), total eNOS
(1:100 - BD bioscience – cat#: 610297), β-Tubulin (1:2000 - Invitrogen - cat#:
MA5-16308) and β-actin (1:5000 - Cell Signaling Technology – cat#: 4967) were
diluted in 1% casein/TBST solution and membranes were submerged in the
antibody solution overnight on a shaker at 4oC. Secondary antibodies (Li-Cor
biotechnology) were diluted (1:15,000) in 1% casein/TBST solution and
membranes were allowed to incubate for 2 hours at room temperature on a
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shaker. Membranes were visualized on the Li-Cor Odyssey Clx membrane
scanner and quantified using ImageStudio software version 5.2.5. All western
blots were represented as a fold changed compared to wild type. To calculate
this, first the ratio between the protein of interest and the loading control (β-actin
or β-tubulin) was determined. The ratio for the WT was then average. Lastly, WT
and experimental samples were all divided by the average WT ratio to determine
the fold change.
For phospho-myosin light chain western blotting, vessels were dissected
then placed in 5% trichloroacetic acid/acetone solution and immediately placed in
a -80oC freezer until time to homogenize tissue. On the day of tissue
homogenization, vessels were taken out of the freezer and allowed to thaw at
room temperature for 30 minutes. After 30 minutes, vessels were moved into a
100% acetone solution and sat at room temperature for 30 minutes. Vessels
were taken out and weighed so that an approximately equal mass of vessel could
be used. Vessels were homogenized in 50 μL of solution containing: 8M urea,
20mM tris-base, 22mM glycine, 10mM DTT, 5mM EGTA, 5mM Na2EDTA.
Samples were spun at 10,000 RPM for 15 minutes at room temperature. The
supernatant was collected and an equal volume was mixed with Lamelli sample
buffer and loaded onto a 12% PAGE gel. The gel ran at 125V for two hours. The
gel was transferred overnight onto a PVDF membrane in buffer containing:
25mM Tris-base, 192mM glycine, and 20% methanol. The next day, membranes
were taken out and blocked in 1% BSA in TBS. Phospho-myosin light chain (cell
signaling technology - cat#: 3674S) was diluted in 1% casein/TBST solution
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(1:250) and incubated overnight at 4oC. The next day, membranes were
incubated in Li-Cor secondary antibody (1:15,000) in 1% casein/TBST buffer for
2 hours. Membranes were visualized on the Li-Cor Odyssey Clx membrane
scanner and quantified using ImageStudio software version 5.2.5. Immediately
after membrane visualization, membranes were stripped using Li-Cor NewBlot IR
stripping buffer according to manufacturer’s protocol. Membranes were blocked
with 1% BSA/TBS blocking buffer for 1 hour followed by incubation with myosin
light chain antibody (1:250 - cell signaling technology - cat#: 3672S) in 1%
casein/TBST solution. Secondary antibody incubation and quantification was
performed the same as for phospho-myosin light chain. The values were
represented as a fold change using the same calculations as described above.

Reverse Transcription Polymerase Chain Reaction: Mesenteric arteries and
RIA were dissected and flash frozen in liquid nitrogen and stored at -80oC.
Messenger RNA was obtained using the miRNeasy micro kit (Qiagen – cat:
217084). Equal amounts of RNA were used to generate cDNA using the
Quantitech cDNA synthesis kit (Qiagen). Taqman primer/probes for Cyp4a12
(Mm00514494_m1), Myh11 (Mm00443013_m1), Tagln (Mm00441661_g1),
Acta2 (Mm00725412_s1); Col4a4 (Mm00801574_m1); Col1a1
(Mm00801666_g1), Ace (Mm00802048_m1), and Tuba1a (Mm00846967_g1)
were purchased from ThermoFisher. For all reactions, 2 μl cDNA was mixed in
18 μl of master mix containing: 1 μl of 20X primer/probe, 10 μl 2X Taqman
advance fast master mix and 7 μl nuclease free water. The thermal profile for
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qPCR reaction was: 50oC for 2 minutes, 95oC for 20 seconds and 40 cycles of
95oC for 3 seconds and 60oC for 30 seconds. Relative expression was calculated
using the 2(-ΔΔCt) method. Ct values were determined using the QuantStudio 3
RT-PCR machine for all genes of interest. The change in Ct (ΔCt) values were
determined by taking the difference between the experimental gene from the
housekeeper gene (Tuba1a). After the determination of the ΔCt, the ΔΔCt value
was calculated. To do this, the WT ΔCt was averaged. The difference between
the ΔCt values for each mouse and the average ΔCt values was determined.
Lastly, 2 was raised to the (-ΔΔCt) to determine the relative expression of the
gene of interest.

20-HETE Measurements: 20-HETE was quantified by LC-MS/MS-based
lipidomics. Blood was withdrawn at the end of the experiment by aspiration from
the inferior vena cava. Briefly, animals were anesthetized with isoflurane, and
their abdomens were swabbed with 70% alcohol and opened by a midline
longitudinal incision. Next, the caudal (inferior) vena cava was identified and
punctured, and blood was drawn into a heparinized syringe. Blood was
centrifuged at 2,000 rpm for 15 min to separate the plasma. Plasma samples
were subjected to chloroform-methanol extraction and alkali hydrolysis for
assessment of free and esterified 20-HETE. Renal preglomerular arteries and
mesenteric arteries were microdissected and incubated in Kreb’s bicarbonate
buffer, pH 7, 1 mM NADPH at 37°C for 1 h. Tissue incubations were terminated
with 2 volumes of cold methanol, internal standards were added, and samples
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were kept at -80°C. Urine was mixed with two parts of methanol before LCMS/MS. Eicosanoids were extracted with solid-phase Strata-X Polymeric
Reversed Phase 60-mg cartridges (Phenomenex, Torrance, CA). Identification
and quantification of 20-HETE were performed on a Shimadzu Triple Quadrupole
Mass Spectrometer LCMS-8050 equipped with a Nexera UHPLC using multiple
reaction monitoring mode. MS conditions were ionization mode: negative heated
electrospray (HESI); applied voltage: -4.5 to approximately -3 kV; nebulizer gas:
3.0 L/min N2; drying gas: 5.0 L/min N2; heating gas: 12.0 L/min air; interface
temperature: 400°C; desolvation line temperature: 100°C; heat block
temperature: 500°C; and internal standard: d6 20-HETE. UHPLC conditions were
as follows: analytical column measures were Zorbax Eclipse Plus C18 RRHD
(50-mm length x 2.1-mm inner diameter, 1.8 μm); mobile phase A: 95% water5% acetonitrile 0.05% acetic acid; mobile phase B: acetonitrile 0.05%; time
program 40% B (0 min) → 75% B (3 min) → 85% B (7.5 min); flow rate: 0.4
mL/min; injection volume: 5 μL; column oven temperature: 40°C. Synthetic
standards were used to obtain standard curves (0.5–500 pg) for each compound.
These standard curves were used to calculate final concentrations of 20-HETE.
All solvents were HPLC grade or higher.

Statistics: All values are represented as mean ± SEM. Statistical analysis was
performed on GraphPad Prism 8 (version 8.4.3). Two-tailed student t-test was
used to determine significance between two groups. One-way ANOVA with
Tukey post-hoc test was used to compare differences between three or more
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means. 2-way ANOVA repeated measures with Sidak’s post hoc test was used
for phenylephrine, acetylcholine and sodium nitroprusside dose-response
analysis. For wire and pressure myography experiments, both number of mice
(N) and number of vessels (n) were reported. Experiments that compared vessel
reactivity between two genotypes (WT and Myh11-4a12 mice) use N for
statistical calculations. Experiments that assessed the effectiveness of AAA on
acetylcholine induced relaxation within one genotype used n for statistical
calculations. EC50 values from phenylephrine cumulative dose response curves
were calculated and were compared using one-way ANOVA with Tukey post-hoc
test. Rmax values from acetylcholine or SNP induced relaxation were compared
using one-way ANOVA with Tukey post-hoc test. p-values <0.05 were
considered to be statistically significant.
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Results:
Aim 1: To determine if smooth muscle-specific overexpression of Cyp4a1220-HETE synthase causes hypertension and vascular dysfunction.

Myh11-Cre(+/-)-Cyp4a12-Flox(+/wt) (Myh11-4a12) had significantly elevated
Cyp4a12 levels in vessels that resulted in elevated 20-HETE
Myh11-4a12 mice had a significant increase of Cyp4a12 mRNA
expression in resistant vessels (mesenteric arteries: 8.62 ± 1.26 vs 1.44 ± 0.30;
RIA: 5.95 vs 1.12, relative expression to Tuba1a, p<0.0001) compared to WT
(Figure 1A and 1B). The increase in expression was not observed in liver
(Figure 1C: 1.56 ± 0.54 vs 1.91 ± 0.37 relative expression to Tuba1a). The
overexpression of mRNA translated to increased Cyp4a protein levels when
comparing mesenteric arteries of Myh11-4a12 mice to WT (Figure 2A: 1.95 ±
0.21 vs 1.00 ± 0.21 Cyp4a/β-actin fold expression, p<0.05). Increases in Cyp4a
protein expression were not observed in livers (Figure 2B: 1.00 ± 0.15 vs 1.00 ±
0.15, Cyp4A/β-actin fold change). Furthermore, elevated Cyp4a12 was
associated with increased 20-HETE levels in mesenteric arteries (3334 ± 891
pg/mg protein vs 545 ± 197 pg/mg protein, p<0.05), RIA (1895 ± 376 pg/mg
protein vs 242 ± 63 pg/mg protein, p<0.05), and plasma (391 ± 52 pg/mL vs 242
± 18 pg/mL, p=0.05) without any changes in urinary levels (117 ± 29 pg/mL vs
146 ± 27 pg/mL, p=0.48) (Figure 3A-D).
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Myh11-4a12 mice are hypertensive and have impaired vascular function.
Systolic blood pressure (SBP) measured at 8-10-weeks of age was
significantly higher in Myh11-Cyp4a12 mice compared to WT mice (Figure 5A:
144 ± 2 vs 130 ± 1 mmHg, p<0.0001). Isolated RIA from Myh11-4a12 mice
displayed impaired acetylcholine-induced relaxation after precontraction with
phenylephrine compared to RIA from WT mice (Figure 5B: Maximal relaxation:
47% ± 6.9 vs. 80% ± 4.3 p<0.001). Renal interlobar arteries from Myh11-4a12
mice given a NO donor (SNP) were able to relax to a degree similar to WT
(Figure 5C: Maximal relaxation: 85% ± 4.0 vs 80% ± 9.0) Measurements of
vessel wall thickness were taken to assess 20-HETE’s effects on vascular
remodeling. Myh11-4a12 mice had an increase media:lumen ratio compared to
WT (Figure 6A: 0.332 ± 0.027 vs 0.164 ± 0.010, p<0.0001, student t-test). Media
thickness (Figure 6B: 25.70 ± 1.22 μm vs 15.00 ± 0.71 μm, *p<0.05) and media
cross-sectional area (Figure 6C: 15718 ± 1496 μm2 vs 10407 ± 660 μm2,
*p<0.05) were also elevated in Myh11-4a12 mice compared to WT mice.

Markers of smooth muscle cell contraction and NO signaling were altered
in Myh11-4a12 mice.
20-HETE has been documented to have multiple actions on vessels to
increased contractility and impaired relaxation. Phosphorylation of myosin light
chain at serine 19 was used as a marker for increased cellular signaling for
VSMC contraction. Mesenteric arteries from Myh11-4a12 mice had a 40%
increase in phosphorylation of myosin light chain compared to WT mice (Figure
7: 1.40 ± 0.13 vs 1.00 ± 0.08 Ser19 p-MLC/total-MLC fold change, p<0.05).
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Phosphorylation of eNOS was used as a marker for EC cell function and
enhanced relaxation. In aortas of Myh11-4a12 mice, there were reductions in
both phosphorylated and total eNOS expression that was significantly lower than
WT mice (Figure 8: 0.43 ± 0.19 vs 1.23 ± 0.26 Serine 1177/β-tubulin fold
change, *p<0.05 and 0.57 ± 0.14 vs 1.00 ± 0.08 total eNOS/ β-tubulin fold
change).
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Figure 1: Myh11-4a12 mice display overexpression of Cyp4a12 in vessels.
RT-PCR result: A) mesenteric artery (N=14/group; ***<0.001 student t-test), B)
RIA (N=6/group, *<0.05 t-test) and C) Liver (N=6 wild type, n=7 Myh11-4a12)
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Figure 2: Myh11-4a12 mice have elevated Cyp4a protein in vessels.
A) Mesenteric artery (N=4/group, *p<0.05 compared to wild type, student t-test)
but no difference was observed in B) liver (N=8/group, student t-test).
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Figure 3: Myh11-4a12 mice display elevated 20-HETE.
A) Mesenteric arteries (N=5 WT, n=6 Myh11-4a12), B) RIA (N=3/group), C)
Plasma (N=4 WT, N=6 Myh11-4a12) but not in D) Urine (N=5/group). Mean ±
SEM student t-test *p<0.05.
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Figure 4: Mice with smooth muscle-specific overexpression of Cyp4a12 are
hypertensive.
Baseline systolic blood pressure measurement. N=22 Wild type; N=27 Myh114a12. ****p<0.0001, student t-test.
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Figure 5: Mice with smooth muscle-specific overexpression of Cyp4a12
have impaired relaxation.
A) Acetylcholine-induced relaxation after phenylephrine precontraction. Wild type
N=13 mice, n=26 vessels and Myh11-4a12 N=15 mice, n=28 vessels.
***p<0.001, t-test. B) Administration of SNP improved relaxation of vessels with
overproduction of 20-HETE. Wild Type: n=3 mice; Myh11-4a12: n=4 mice. t-test.
Means ± SEM,
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Figure 6: Renal interlobar artery measurements of vascular remodeling are
elevated in Myh11-4a12 mice.
A) Media:lumen ratio, B) Media thickness, and C) Media cross-sectional area.
Wild type N=12 mice, n=24 vessels, Myh11-4a12 N=14 mice, n=28 vessels;
**p<0.01, ***p<0.0001, student t-test.
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Figure 7: Baseline expression of myosin light chain phosphorylation at
serine 19 in mesenteric arteries were elevated in Myh11-4a12 mice.
N=12 wild type; N=10 Myh11-4a12. *p<0.05 student t-test.
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Figure 8: Baseline expression of phosphorylated and total eNOS was
reduced in aortas of Myh11-4a12 mice.
A) Serine 1177 phosphorylated eNOS to β-tubulin ration and B) total eNOS to βtubulin. N=6/group, *p<0.05, student t-test
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Aim 2: To determine if the vascular pathology in Myh11-4a12 mice is 20HETE-dependent.

Administration of AAA decreased systolic blood pressure and improved
vascular function in mice with smooth muscle-specific Cyp4a12
overexpression.
Myh11-4a12 mice were hypertensive compared to WT on day 0 (Figure 9:
Myh11-4a12 ((combine): 146 ± 3 mmHg vs WT – vehicle: 132 ± 3 mmHg,
p<0.001, student t-test). Twelve days of AAA treatment normalized SBP to WT
levels with values starting to decrease at day 4 (Day 12: Myh11-4a12 – AAA 126
± 1 vs 129 ± 1 mmHg). Wild type mice on AAA had no changes in SBP
compared to WT mice on vehicle (data not shown). Administration of AAA
appeared to have no effect on 20-HETE levels in the plasma. Myh11-4a12 mice
had elevated 20-HETE levels compared to WT (Figure 10: 298 ± 35 vs 157 ± 23
pg/mL plasma, p<0.05) however, Myh11-4a12 mice on AAA (298 ± 58 pg/mL
plasma) had a similar value compared to Myh11-4a12 mice on vehicle.
Fluid balance and urinary sodium excretion was also assessed to
determine if the blood pressure lowering effect of AAA was also due to changes
in the renal handling of salt and fluid. Mean values for water consumption
appeared similar between the three groups (Figure 11A: Wild type – vehicle:
0.38 vs Myh11-4a12 – vehicle: 0.38 vs Myh11-4a12 – AAA 0.37 mL/gram body
weight/24 hours). Urine volume was similar between WT and Myh11-4a12 mice
on vehicle (Figure 11B: 52.0 vs 55.6 μL/gram body weight/24 hours). Urine
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excretion appeared to increase in Myh11-4a12 mice on AAA (75.6 μL/gram body
weight/24 hours), however, no conclusion was made due to the small sample
size. Similar trends were observed when measuring urinary sodium excretion.
Average values for urinary sodium excretion were similar between Myh11-4a12
and WT mice on vehicle (6.91 μmole/gram body weight vs 7.71 μmole/gram body
weight/24 hours). While there was an upward trend in sodium excretion in
Myh11-4a12 mice on AAA, no conclusions could be determined due to the small
sample size (11.35 μmole/gram body weight/24 hours).
After day 12, mice were sacrificed and RIA were isolated for wire
myography. RIA from Myh11-4a12 mice displayed impaired acetylcholineinduced relaxation compared to WT mice (Rmax: 67% ± 5 vs 90% ± 2,
P<0.0001). Myh11-4a12 mice on AAA had improved acetylcholine relaxation with
values similar to WT (Rmax: 96% ± 1) (Figure 12A). Changes in phenylephrineinduced contractions were also observed. RIA from Myh11-4a12 mice were more
sensitive to phenylephrine-induced contraction compared to WT (EC50: 1.63 x 107

μM vs. 5.00 x 10-7 μM, p<0.0001). The sensitivity of phenylephrine for Myh11-

4a12 mice on AAA (EC50: 4.22 x 10-7 μM) was not different compared to WT
(Figure 12B).
Ex vivo experiments were performed to assess the direct actions of AAA
in RIA to promote relaxation. Both WT and Myh11-4a12 vessels were treated
with vehicle first followed by 10 μM AAA. Wild type vessels had no apparent
difference in the ability to relax after acetylcholine-induced relaxation (Figure
13A). On the other hand, Myh11-4a12 mice displayed improved relaxation

41

response after acetylcholine administration. Myh11-4a12 vessels had a maximal
% relaxation of 40 ± 6% after vehicle treatment. AAA pretreatment resulted in
improved relaxation (63 ± 7%, p<0.05) (Figure 13B). Comparisons were made
between the four groups at the highest does of acetylcholine administration.
Myh11-4a12 vessels on vehicle had significantly impaired relaxation response
compared to WT either on vehicle or AAA (Figure 13B: 40 ± 6% vs. 67 ± 6 WT –
vehicle and 64 ± 6% WT – AAA, p<0.05). AAA was able to significantly improve
the ability of the vessels to relax in Myh11-4a12 mice. Myh11-4a12 vessels after
AAA had similar relaxation values compared to WT on vehicle or AAA (Figure
13C: 63 ± 4%)

AAA administration improved media:lumen ratio but did not affect media
thickness or cross-sectional area of RIA
Renal interlobar arteries from Myh11-4a12 mice had a media:lumen ratio
that was significantly higher than WT (Figure 14A: 0.277 ± 0.025 vs 0.163 ±
0.006, P<0.0001). RIA from AAA-treated Myh11-4a12 mice showed a reduction
in media:lumen ratio (0.129 ± 0.013, p<0.05) when compared to Myh11-4a12 on
vehicle (Figure 14A). Analysis of media wall thickness and media cross-sectional
area show that AAA did not have an effect on vessel wall thickness. Both Myh114a12 mice either on vehicle or AAA had a thicker media (Figure 14B: 23.85 ±
2.25 μm and 20.72 ± 1.37 μm vs 15.86 ± 0.83 μm, p<0.0001 WT - vehicle vs
Myh11-4a12 - vehicle and p<0.05 WT - vehicle vs Myh11-4a12 – AAA) and
cross-sectional area (Figure 14C: 15114 ± 1871 μm2 and 14268 ± 1259 μm2 vs
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10560 ± 641 μm2, p<0.05 WT - vehicle vs Myh11-4a12 - vehicle and p=0.08 WT vehicle vs Myh11-4a12 – AAA) compared to WT. Western blot analysis for
myosin heavy chain 11, a marker of vascular smooth muscle cell differentiation,
is in line with these results. Myh11-4a12 mice either on vehicle or AAA appeared
to have higher myosin heavy chain expression compared to WT on vehicle
(Figure 14D: 3.10 ± 0.98 Myh11/β-tubulin fold change and 3.25 ± 0.72 Myh11/βtubulin fold change vs 1.00 ± 0.10 Myh11/β-tubulin fold change).

Markers of VSMC differentiation were elevated in Myh11-4a12 mice.
At baseline, the vessel wall was thicker in Myh11-4a12 mice compared to
WT mice. This may be due to 20-HETE’s ability to cause VSMC proliferation
which increases the number of mature cells within the vessel wall. To determine
this, markers of VSMC differentiation [Myh11, Sm22a, Acta2] were measured in
renal interlobar arteries (Figure 15). Myh11 (RIA: 1.67 ± 0.22 vs 1.18 ± 0.22,
relative expression to tuba1a), Tagln (2.13 ± 0.25 vs 1.17 ± 0.26 relative
expression to tuba1a, p<0.05 t-test), and Acta2 (RIA: 1.94 ± 0.23 vs 1.14 ± 0.20,
relative expression tuba1a, p<0.05 t-test) mRNA expression were all elevated
compared to WT mice.
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No differences in collagen expression were observed between Myh11-4a12
and wild type mice.
20-HETE has been documented to promote increases in collagen
synthesis in rats (Soler et al., 2018). Messenger RNA of Collagen I and Collagen
IV were assessed to determine if increase in collagen synthesis was occurring
which may contribute to the stiffening of the vessels and increase in blood
pressure. Collagen I (0.76 ± 0.28 vs 1.25 ± 0.25, relative expression to Tuba1a)
and collagen IV (1.12 ± 0.29 vs 1.25 ± 0.30, relative expression to Tuba1a) were
not different between Myh11-4a12 and WT mice in mesenteric arteries (Figure
16).
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Figure 9: Administration of a 20-HETE receptor antagonist (AAA) was able
to lower blood pressure after 12 days.
A) Wild Type or Myh11-4a12 mice underwent either vehicle treatment or AAA
(10mg/kg/day) treatment for 12 days. N=12 Wild type – vehicle; N=11 Myh114a12 – vehicle; N=14 Myh11-4a12 – AAA. *p<0.05 of Myh11-4a12 compared to
wild type. #p<0.05 Myh11-4a12 – vehicle to Myh11-4a12 – AAA. 2-way ANOVA
with Tukey post-hoc test.
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Figure 10: Plasma 20-HETE levels were unchanged after 12-day AAA
treatment.
Wild type - Vehicle N=13, Myh11-4a12 - Vehicle N=15, Myh11-4a12 – AAA
N=10. *p<0.05 one-way ANOVA vs wild type - vehicle.
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Figure 11: Urine volume and sodium excretion in WT and Myh11-4a12 mice
treated with and without AAA.
A) water consumption, B) urine volume, C) urinary sodium. Wild type – vehicle
N=3, Myh11-4a12 - vehicle N=2, Myh11-4a12 – AAA N=3.
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Figure 12: Vascular activity was improved after 12 days of AAA treatment.
A) Dose response acetylcholine induced relaxation on RIA after 12 days of AAA
treatment. Wild Type – vehicle N=7 mice, n=14 vessels; Myh11-4a12 – vehicle
N=7 mice, n=14 vessels; Myh11-4a12 – AAA N=7 mice, n=14 vessels.
***p<0.001 Wild Type - vehicle vs Myh11-4a12 -vehicle; ####p<0.0001 Myh114a12 - vehicle vs Myh11-4a12 – AAA. One-way ANOVA. B) Dose response
phenylephrine induced contraction on RIA after 12 days of treatment. Wild Type
– Vehicle N=7 mice, n=14 vessels; Myh11-4a12 – vehicle N=9 mice, n=18
vessels; Myh11-4a12 – AAA N=6 mice, n=12 vessels. ***p<0.001, ##p<0.01 Oneway ANOVA
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Figure 13: Myh11-4a12 mice had improved relaxation with AAA treatment
ex vivo.
A) Wild type N=3 mice, n=9 vessels. B) Myh11-4a12 N=6 mice, n=17 vessels
vehicle and n=16 vessels AAA treatment. *p<0.05 2-way ANOVA. C)
comparisons of all treatments at 10-4M acetylcholine. P<0.05 one-way ANOVA.
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Figure 14: Myh11-4a12 mice have an elevated media:lumen ratio that was
reduced with AAA treatment, however, AAA did not reduce the thickness of
the vessel.
Renal interlobar arteries underwent pressurized myography and the inner and
outer diameters were measured. A) media:lumen ratio; B) media thickness; C)
media cross-sectional area (CSA). Wild type – vehicle N=9 mice, n=18 vessels
Myh11-4a12 – vehicle N=7 mice, n=14 vessels, Myh11-4a12 – AAA N=8 mice,
n=16 vessels. Mean ± SEM one-way ANOVA *p<0.05, **p<0.01, ***p<0.001. D)
Western blot analysis for smooth muscle-specific myosin heavy in mesenteric
arteries. N=5 wild type - vehicle, N=4 Myh11-4a12 – vehicle, N=5 Myh11-4a12 –
AAA. Mean ± SEM, one-way ANOVA.
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Figure 15: Increases in markers of VSMC differentiation were observed in
RIA of Myh11-4a12 mice.
A) Myh11 (N=6/group B) Tagln (wild type: N=7; Myh11-4a12: N=6); C) Acta2
(N=6/group) Means ± SEM, *p<0.05, **p<0.01, ***p<0.001 student t-test.
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Figure 16: No differences in collagen expression were observed between
Myh11-4a12 and wild type mice.
A) Collagen I and B) Collagen IV. Wild Type: N=11; Myh11-4a12: N=8. Means ±
SEM, student t-test.
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Aim 3: To explore cellular mechanisms underlying the increased
contractility of arteries from mice with smooth muscle-specific
overexpression of Cyp4a12.

No changes were observed in ACE mRNA expression between wild type
and Myh11-4a12 mice.
ACE expression has been shown to increase with elevated 20-HETE.
Increases in ACE result in increases in angiotensin II which may have a direct
action on vessels to cause contraction. ACE is primarily expressed in the
endothelium, however, there is also ACE expression in the VSMC (Fishel et al.,
1995). After measuring Ace mRNA in mesenteric arteries, there was no
difference between Myh11-4a12 and WT mice (Figure 17: 1.36 ± 0.26 vs 1.03 ±
0.126, relative expression to tuba1a)

Myh11-4a12 mice appeared to have reductions in eNOS activation which
was increased with AAA treatment.
Myh11-4a12 mice with elevated 20-HETE have impaired relaxation to
acetylcholine, and administration of a 20-HETE receptor antagonist improves the
relaxation of the vessel to a level similar to wild type. Furthermore, administration
of a NO donor allowed the vessel from Myh11-4a12 mice to relax to a degree
similar to WT. This suggests that vessels from Myh11-4a12 mice have an
impairment in NO bioavailability. The inhibition of eNOS activation is one
possible reason for this impairment. Activation of eNOS was measured by
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phosphorylation of eNOS at Serine 1177 via western blotting. Myh11-4a12 mice
appeared to have reductions in Serine 1177 phosphorylation compared to wild
type in aorta (Figure 18A: 0.43 ± 0.19 vs 1.23 ± 0.26, Ser1177 p-eNOS/β-tubulin
fold change). Myh11-4a12 mice also appeared to have lower total eNOS
expression compared to WT (Figure 18B: 0.57 ± 0.14 vs 1.00 ± 0.08 total
eNOS/β-tubulin fold change). AAA treatment appeared to increase
phosphorylation (1.42 ± 0.58, Ser1177 p-eNOS/β-tubulin fold change) and total
eNOS (1.20 ± 0.58, total eNOS/β-tubulin fold change) levels of Myh11-4a12 mice
to a value greater than WT. Vasodilator-stimulated phosphoprotein (VASP)
phosphorylation at Serine 239 was also measured because it is an indicator that
NO from the EC is able to reach the VSMC. Myh11-4a12 mice had reductions in
VASP phosphorylation compared to WT (0.61 ± 0.09 vs 1.00 ± 0.04, Ser239 pVASP/total VASP fold change, p<0.01) which was unchanged when Myh11-4a12
mice were given AAA (Figure 18C: 0.63 ± 0.07, Ser239 p-VASP/total VASP fold
change). In mesenteric arteries, changes in phosphorylation of eNOS were also
observed. Myh11-4a12 mice appeared to have reduced eNOS phosphorylation
(Figure 19: 0.57 ± 0.06 vs 1.00 ± 0.23 Ser1177 p-eNOS/total eNOS, p=0.15) and
Myh11-4a12 mice that were given AAA had increase phosphorylated eNOS
levels (1.07 ± 0.08 p-eNOS/total eNOS, p=0.20). Unlike aortas, there were no
differences in total eNOS protein expression between the three groups.
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Administration of the 20-HETE receptor antagonist was able to reduce
phosphorylation of myosin light chain.
20-HETE’s ability to change the sensitivity of RIA to phenylephrine
suggests that 20-HETE can mediate actions to cause changes in
phosphorylation state of myosin light chain. When probing for the
phosphorylation of Serine 19 on the regulatory subunit of myosin light chain,
there was approximately a 60% increase in the Myh11-4a12 group compared to
wild type (1.60 ± 0.23 vs 1.00 ± 0.06 Ser19 p-MLC/total MLC fold change, p<0.05
one-way ANOVA). Myh11-4a12 mice treated with AAA had reduced phosphomyosin light chain levels (0.94 ± 0.11, Ser19 p-MLC/total MLC fold change,
p<0.05 vs Myh11-4a12 – vehicle, one-way ANOVA) that were similar to wild type
(Figure 20).

20-HETE was able to increase Rho-kinase activity which was attenuated
with AAA.
Upstream of myosin light chain is Rho-kinase (ROCK). RhoA-GTP
activates ROCK which causes the phosphorylation and inhibition of myosin light
chain phosphatase. Inhibition of myosin light chain phosphatase allows for the
phosphate group on myosin light chain to stay on so it remains in a contractile
state. ROCK1 protein was measured in RIA and there was a 60% increase in
Myh11-4a12 mice compared to wild type (Figure 21: 1.60 ± 0.21 vs 1.00 ± 0.18,
p<0.05). AAA treatment did not affect the protein expression of ROCK1 (data not
shown). Although AAA was not able to decrease ROCK1 expression, it is
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possible that AAA can change activity of ROCK. To assess this, WT RIAs were
used and pressure myography was performed to asses AAA and ROCK inhibitor,
Y-27632, on 20-HETE-induced changes in myogenic response. Treating RIA with
20-HETE produced a downward shift in the absolute ID and the normalized ID
curves (Figure 22 A&B). Co-treatment with 20-HETE plus AAA or ROCK
inhibitor (Y-27632) shifted the curve upward overlapping the vehicle treated
vessels. Lastly, combined treatment of 20-HETE with AAA and ROCK inhibitor
did not result in any further upward shifts in either the absolute ID or normalized
ID curves. The most significant changes happened at pressure of 80 mmHg and
100 mmHg (Figure 23). At 80 mmHg, 20-HETE reduced the absolute ID (106 ±
2.5 μm vs 124 ± 2.6 μm, p<0.01) and the normalized ID (42 ± 0.86 % vs 48 ±
0.79%, p<0.001) significantly compared to WT. Co-treatment with 20-HETE plus
AAA (absolute ID: 124 ± 2 μm, p<0.001; normalized ID: 48.8 ± 0.89%, p<0.0001)
or Y-27632 (absolute ID: 126 ± 3 μm, p<0.001; normalized ID: 49 ± 1.2%,
p<0.0001) increase the absolute ID and the normalized ID significantly compared
to 20-HETE only. Treatment of RIA with 20-HETE plus AAA and Y-27632 did not
produce any further increase in absolute ID (113 ± 4.6 μm, p<0.001 vs 20-HETE
treatment) or normalized ID (49 ± 1.4%, p<0.0001 vs 20-HETE treatment).
Similar results were observed at 100 mmHg. Administration of 20-HETE in the
bath reduced the absolute ID (90 ± 3.3 vs 106 ± 3.2 μm, p<0.05) and the
normalized ID (33 ± 1.1 vs 39 ± 0.94%, p<0.01) compared to vehicle treated.
Adding either AAA (Absolute ID: 109 ± 3.4 μm, p<0.01; normalized ID: 41 ±
0.97%, p<0.001) or Y-27632 (Absolute ID: 108 ± 3.7, p<0.01; normalized ID: 40 ±
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1.1%, p<0.001 ) blunted the increased myogenic response due to 20-HETE.
Treatment with 20-HETE, AAA and Y-27632 did not further increase the absolute
ID (113 ± 4.6 μm, p<0.001) and normalized ID (41 ± 1.5%, p<0.001).
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Figure 17: No differences in ACE mRNA expression were observed
between Myh11-4a12 and wild type mice in mesenteric arteries.
Wild Type: N=5; Myh11-4a12: N=8. Means ± SEM, student t-test.

58

Wild Type - Vehicle

Myh11-4a12 - Vehicle

Myh11-4a12 - AAA

140 kDa
140 kDa
55 kDa

S1177 peNOS
Total eNOS

2.0

B)

*

p=0.08

2.0

Fold Change
(total eNOS/β-Tubulin)

A)

Fold Change
(Ser1177 p-eNOS/β-Tubulin)

β-tubulin

1.5
1.0
0.5

p=0.25

1.0
0.5
0.0

0.0
ic
eh
V
-

e
cl
hi
e
-V

le

12
2
4a
1
4a
11
Ty
1yh
1
ild
M
yh
W
M
pe

*

1.5

-A

A

A

ild
W

Wild Type - Vehicle

pe
Ty

Myh11-4a12 - Vehicle

eh
-V

M

yh

ic

le

-4
11

2
a1

cl
hi
e
-V
M

e

a1
-4
1
1
yh

2

-A

A

A

Myh11-4a12 - AAA

50 kDa
50 kDa
55 kDa

Ser239 pVASP
Total VASP

C)

Fold Change
Ser239 p-VASP/total VASP

β-tubulin
1.5

1.0

NS

**
0.5

11
-4

a1
2

-A

A
A

ic
le
-V
eh
M
yh

4a
12

M
yh
11
-

W
ild

Ty
pe

-V
eh

ic
le

0.0

Figure 18: Western blot analysis of eNOS and VASP phosphorylation in
aorta.
A) Serine 1177 phospho-eNOS/β-tubulin and B) total eNOS/ β-tubulin. N=6 wild
type – vehicle and Myh11-4a12 – vehicle; N=7 Myh11-4a12 – AAA, *p<0.05 oneway ANOVA. C) Serine 239 phospho-VASP/total VASP. N=5 wild type – vehicle
N=4 Myh11-4a12 – vehicle and Myh11-4a12 – AAA, **p<0.01, One-way ANOVA.

59

Wild Type - Vehicle

Myh11-4a12 - Vehicle

Myh11-4a12 - AAA

140 kDa
140 kDa
55 kDa

S1177 peNOS
Total eNOS

Fold Change
(Ser1177 p-eNOS/total eNOS)

β-tubulin

1.5

p=0.15
p=0.20

1.0

0.5

0.0

ild
W

pe
y
T

e
cl
i
eh
V
-

M

11
h
y

12
a
-4

e
V
-

e
cl
i
h

M

4
11
yh

2
a1

-A

A

A

Figure 19: Phosphorylation of eNOS at serine 1177 after 12 days of AAA
treatment in mesenteric arteries of Myh11-4a12 mice.
Wild type – vehicle: N=5, Myh11-4a12 – vehicle: N=5, Myh11-4a12 – AAA: N=5.
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Figure 20: Myh11-4a12 mice have elevated phosphorylation of myosin light
chain that was reduced with 12 day AAA treatment.
A) Western blot analysis of Serine 19 phospho-myosin light chain expression in
mesenteric arteries after 12-day AAA treatment (N=7 Wild Type – Vehicle and
Myh11-4a12-vehicle; N=6 Myh11-4a12 - AAA, one-way ANOVA.
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Figure 21: ROCK1 protein expression was elevated in Myh11-4a12 mice.
Wild type: N=5; Myh11-4a12: N=6, *p<0.05, student t-test.
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Figure 22: Addition of AAA or Y-27632 prevented 20-HETE-mediated
increase in myogenic tone of RIA from WT mice.
A) absolute internal diameter (ID) and B) percent myogenic tone. Vehicle, 20HETE only, 20-HETE + AAA, 20-HETE + Y-27632 – N= 6 mice, n=12 vessels;
20-HETE + AAA + Y-27632 – N = 4 mice, n=8 vessels.
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Figure 23: Absolute internal diameter (ID) and percent myogenic tone
values of WT RIA at 80mmHg and 100mmHg.
A) absolute and B) normalized ID at 80 mmHg and C) absolute and D)
normalized ID at 100 mmHg. Vehicle, 20-HETE only, 20-HETE + AAA, 20-HETE
+ Y-27632 – N = 6 mice, n=12 vessels; 20-HETE + AAA + Y-27632 – N = 4 mice,
n=8 vessels. *p<0.05, **p<0.01, ***p<0.001 vs vehicle treated. ##p<0.01,
###p<0.001 vs 20-HETE treated one-way ANOVA.
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Discussion
The present study provides evidence to show the actions of 20-HETE
within the vascular smooth muscle cell to promote hypertension and vascular
dysfunction. The main findings of this study include: 1) vascular smooth musclespecific overexpression of Cyp4a12 and increased vascular production of 20HETE was sufficient to promote increases in blood pressure and impairment in
vascular function; 2) treatment with a novel, water-soluble 20-HETE receptor
antagonist (AAA) reversed the pathology associated with 20-HETE
overproduction; 3) elevated 20-HETE changes signaling within the VSMC and
EC which was reversed with AAA treatment. The signaling mechanisms that
were assessed were Rho-kinase-mediated myosin light chain phosphorylation
and NO signaling.
The actions of 20-HETE within the vasculature have been extensively
shown in animal models with global overproduction of 20-HETE. These models
have consistently shown that increased 20-HETE within the vasculature
promotes hypertension and vascular dysfunction. The limitation of using global
models of 20-HETE production is the difficulty to dissect how 20-HETE within
specific cell types contributes to changes in vascular function. The utilization of
animal models with site-specific expression of 20-HETE can better show the
mechanism in which 20-HETE produces changes in vascular function with a
certain cell type.
In this study, the cre/flox system was utilized to target Cyp4a12
overexpression to the smooth muscle cell. The reason for this approach of
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Cyp4a12 overexpression was to overproduce 20-HETE in the primary site of
synthesis (Harder et al., 1994; Gebremedhin et al., 1998). 20-HETE has been
shown to produce effects within the VSMC to change blood pressure and
vascular function in vitro and in models of global overproduction of 20-HETE.
This is the first time that Cyp4a12 was endogenously overexpressed in the
VSMC to produce 20-HETE in a mouse.
The mouse model that was used in the present study was appropriate to
assess the consequence of 20-HETE overproduction generated by the VSMC.
The cre/lox system was used to target Cyp4a12 production, specifically in the
VSMC. The Cyp4a12-flox gene was constructed to have the regulatory unit of the
gene flanked with the LoxP site. In the presence of cre-recombinase, the
regulatory unit of the gene was removed to allow for unregulated production of
Cyp4a12 (Gilani et al., 2020). Cyp4a12-flox expression was targeted to the
VSMC by site-specific cre-recombinase production under the control of the
smooth muscle-specific myosin heavy chain promoter (Myh11-Cre) (Xin et al.,
2002). This was evident when probing for Cyp4a12 expression at the mRNA and
protein level. In mesenteric and RIAs, there was significant increase in Cyp4a12
mRNA expression compared to WT mice. There was also a significant increase
in Cyp4a protein levels in the mesenteric artery compared to WT mice. These
changes were not observed in the liver.
The result of the VSMC-specific overexpression of Cyp4a12 was elevated
20-HETE levels. Elevated 20-HETE levels were observed in mesenteric arteries,
RIA, and plasma; however, no change in 20-HETE was observed in urine. This
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gives evidence that 20-HETE production is directed to the vessels, but the 20HETE produced in the vessels can be found in circulating stores. Mice with
elevated 20-HETE also had elevated systolic blood pressure and impairments in
acetylcholine-induced relaxation. When performing western blots to reinforce the
results from the ex vivo experiments in vessels, changes in eNOS expression in
the aorta and serine 19 phospho-myosin light chain expression were also
observed. Altogether, the results demonstrate that VSMC-specific Cyp4a12
expression results in elevated 20-HETE and impairments in vascular activity,
which contribute to changes in systolic blood pressure.
Global overexpression models of 20-HETE are shown to cause increases
in blood pressure and impairment in vascular reactivity. One model of global
overproduction of 20-HETE is the Cyp4a14-/--mouse. The Cyp4a14-/--mouse has
global overexpression of Cyp4a12, the main 20-HETE-producing enzyme in
mice, and its expression is driven by the androgen promoter. This mouse model
resulted in elevated 20-HETE levels in male mice but not in female (Holla et al.,
2001). Increase in blood pressure and impairment in vascular reactivity are
associated with elevated 20-HETE in these mice. In a report by Pandey et. al.
(2017), they showed that Cyp4a14-/--mice had increases in blood pressure and
changes in phenylephrine-induced contraction that were reversed with a 20HETE antagonist (Pandey et al., 2017).
Another model of constitutive 20-HETE overproduction was the Tie2CYP4F2-Tr mouse model. CYP4F2 is a major 20-HETE-producing enzyme in
humans with CYP4F2 activity associated with hypertension (Ward et al., 2008).
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The investigators were interested in CYP4F2 expression within the vessels which
may contribute to 20-HETE-dependent vascular pathology. In their report, they
generated a mouse model that had CYP4F2 expression controlled by the ECspecific Tie-2 promoter (Cheng et al., 2014). These mice exhibit elevated
CYP4F2 expression with corresponding 20-HETE elevation, specifically in the
EC. There were no differences in blood pressure and acetylcholine-induced
relaxation but there were differences in phenylephrine-induced contraction.
Furthermore, the investigators showed a pro-angiogenic phenotype in the Tie2CYP4F2-Tr mouse. This suggests that EC-specific CYP4F2 expression primarily
drives changes in angiogenesis and changes in vascular function may be
secondary to the actions of 20-HETE in the EC.
Each mouse model has its utilities when studying the mechanism of
vascular impairment dependent on 20-HETE. The Cyp4a14-/- mouse model is a
good model for reliable, global 20-HETE overproduction (CC Wu et al., 2013;
Ding et al., 2013; Pandey et al., 2017). It has been used to identify the ability of
20-HETE to impair vascular function (Ding et al., 2013; Pandey et al., 2017).
However, the limitation of using the Cyp4a14-/- mouse is its inability to identify 20HETE’s action within specific tissue types to promote vascular impairments. The
Tie2-CYP4F2-Tr is one model of 20-HETE overproduction within the EC. It has
been documented that this mouse line was not able to produce any changes in
blood pressure, but was able to promote a pro-angiogenic phenotype (Cheng et
al., 2014). Thus, there are limitations of using the Tie2-CYP4F2-Tr mouse when
it comes to assessing mechanisms of blood pressure. In the present study, the
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Myh11-4a12 mouse showed elevated 20-HETE levels in vessels which were
associated with increases in blood pressure and impairments in vascular
function. Thus, the different phenotypes observed with different mouse models of
20-HETE overproduction are influenced by the site of 20-HETE overproduction.
AAA was used to assess the dependence of 20-HETE on blood pressure,
vascular reactivity and remodeling. In the present study, 12 days of AAA
treatment was sufficient to lower blood pressure to a value similar to the wild type
controls. Phenylephrine-induced contraction and acetylcholine-induced relaxation
both were improved after 12 days of AAA treatment. Ex vivo experiments to
assess AAA direct action on RIA showed that mice with Cyp4a12 overexpression
had improved relaxation compared to untreated mice, and no changes were
observed in WT mice. Interestingly, when assessing vascular remodeling, only
the media:lumen ratio was affected by AAA. Media thickness or cross-sectional
area was unchanged after AAA treatment.
AAA has been documented as a 20-HETE receptor antagonist capable of
lowering blood pressure in models of 20-HETE-dependent hypertension
(Sedláková et al., 2018). In a report by Sedlákova et. al. (2018), they used the
Cyp1a1-Ren-2 rat model that has overproduction of 20-HETE and angiotensin II
(Sedláková et al., 2018). The investigators administered AAA for 12 days in the
drinking water and they showed a significant reduction in systolic blood pressure
compared to untreated hypertensive rats. The reduction in systolic blood
pressure was accompanied by improved renal function. The spontaneous
hypertensive rat is another model of hypertension that is 20-HETE-dependent.
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Two reports showed that AAA treatment in the spontaneous hypertensive rat
lowers blood pressure and improves renal function. In one report, AAA was
administered IV and reductions in mean arterial blood pressure were observed
(Walkowska et al., 2021). The changes in mean arterial blood pressure were
accompanied by improvements in renal blood flow. Another report using the
spontaneous hypertensive rat administered AAA in the drinking water rather than
IV. The authors reported reductions in systolic blood pressure after 36 days of
AAA treatment, although the reduction was not significant compared to the
hypertensive controls (Gawrys et al., 2020). The reduction in systolic blood
pressure was accompanied by improvements in renal function as assessed by
reductions in albuminuria.
Fluid balance and sodium excretion was measured to determine if the
blood pressure lowing effect of AAA had a renal component. Previous reports
suggest that AAA was able to improve renal parameters which contributed to the
lowering of blood pressure (Sedláková et al., 2018; Gawrys et al., 2020;
Walkowska et al., 2021). The goal of this experiment was to examine if AAA can
affect sodium excretion and fluid balance in Myh11-4a12 mice. The Myh11-4a12
mice displayed no differences in 20-HETE levels in the urine compared to WT
mice. Urine volume and sodium excretion were similar between WT and Myh114a12 mice. AAA appeared to increase urine volume and sodium excretion in
Myh11-4a12 mice compared to Myh11-4a12 mice on vehicle. Due to the similar
values between WT and Myh11-4a12 mice and the small sample size, no
conclusions were made surrounding AAA and its effects across the kidney.
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20-HETE within the kidney display effects to promote changes in blood
pressure through regulation of salt and fluid handling. In vivo experiments have
demonstrated 20-HETE’s pro- and anti-hypertensive role in the kidney. In
experiments that manipulate 20-HETE levels acutely, 20-HETE was shown to be
antihypertensive. Elevated 20-HETE within the kidney inhibits Na+/K+--ATPase
(Schwartzman et al., 1985; Nowicki et al., 1997), and NKCC2 (Amlal et al., 1998;
Ito and Roman, 1999). These actions facilitate the reduction of blood pressure
through increased salt and fluid excretion. On the other hand, 20-HETE has been
shown to elevate blood pressure through changes in renal blood flow and sodium
reabsorption in animal models with 20-HETE-dependent hypertension. Animal
models of 20-HETE-dependent hypertension include: 1) Cyp4a14-/- (Quigley et
al., 2009; Pandey et al., 2017), 2) Cyp4a11 transgenic mouse (Savas et al.,
2016), 3) proximal tubule targeted Cyp4a12 (PT-4a12) mouse (Gilani et al.,
2020). The Cyp4a14-/- mouse display reductions in renal blood flow (Pandey et
al., 2017) and increase in activity of the sodium hydrogen exchanger (NHE3)
(Quigley et al., 2009), both which promote sodium and fluid retention. In both the
Cyp4a11 transgenic and PT-4a12 mouse, 20-HETE has been shown to increase
expression of serum- and glucocorticoid-inducible kinase-1 (SGK-1) and increase
activity of the sodium chloride exchanger (NCC) to increase sodium and fluid
reabsorption (Savas et al., 2016; Gilani et al., 2020).
The differences in the actions of 20-HETE on renal function may be due to
the acute vs chronic manipulations of 20-HETE levels. In the experimental
models to address the anti-hypertensive actions of 20-HETE, experiments were
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done on wild type animals (Schwartzman et al., 1985; Nowicki et al., 1997; Amlal
et al., 1998) or the Dahl salt-sensitive hypertensive rat (Ito and Roman, 1999).
The changes in blood pressure have been induced either by exogenous
administration of 20-HETE or pharmacological manipulations to endogenously
increase 20-HETE. In mouse models with 20-HETE-dependent hypertension, 20HETE is elevated in renal microvessels (CC Wu et al., 2013) or urine (Gilani et
al., 2020). 20-HETE in these animal models are constitutively elevated and the
prolonged 20-HETE exposure is associated with compensatory changes in renal
blood flow and salt reabsorption resulting in hypertension.
The mechanism by which 20-HETE promotes smooth muscle cell
contraction has been studied extensively. 20-HETE is able to inhibit the BKCa2+channel to increase levels of intracellular calcium (Lauterbach et al., 2002;
Garcia et al., 2017). This action has been shown to be dependent on 20-HETE
binding to its receptor (GPR75) (Garcia et al., 2017). 20-HETE can increase
activity of Rho-kinase promoting the sensitization of smooth muscle cells to
contraction (Randriamboavonjy et al., 2003). However, there are no current
reports to suggest that this action is mediated by the 20-HETE receptor.
Vascular smooth muscle cells have a unique property in which they can
display one of two phenotypes. On one hand, they can exhibit a synthetic
phenotype in which VSMC are capable of synthesizing proteins to induce
migration and proliferation (D Stec et al., 2007; Orozco et al., 2013). On the other
hand, VSMC can exhibit a contractile phenotype. The phenotype in which the
VSMC is exhibiting can be shown through measurements of VSMC differentiation
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markers. The markers used for the determination of the VSMC phenotype are:
Myh11, Tagln, and Acta2 (Frismantiene et al., 2018). If the VSMC is exhibiting a
synthetic phenotype, the expression of VSMC markers should be lower
compared to controls. If the VSMC is exhibiting a contractile phenotype, the
markers should be elevated compared to controls. The present study suggests
that the Myh11-4a12 mice vessels are in a contractile phenotype (Frismantiene
et al., 2018). Markers of VSMC differentiation were measured and mRNA levels
of Myh11, Tagln, and Acta2 were all elevated compared to wild type mice. The
elevated markers of VSMC differentiation suggest that there are more cells that
are capable of contraction.
To assess the cellular signaling involved in VSMC contraction,
phosphorylation of myosin light chain (MLC) at serine 19 was performed.
Phosphorylation of MLC is the downstream signaling event that needs to occur
before excitation contraction coupling can occur in the VSMC (Driska et al.,
1981). Two reasons why MLC can remain phosphorylated include: 1) increase
intracellular calcium promoting increase MLCK activity (Raina et al., 2009) and/or
2) activation of ROCK signaling which inhibits myosin phosphatase and prevents
the dephosphorylation of MLC (Noma et al., 2012). In the current study, ROCK
expression and activity were assessed because it has not been determined if 20HETE-mediated changes in ROCK activity is receptor mediated.
Myh11-4a12 mice had elevated phosphorylation levels compared to wild
type and AAA treatment was able to reduce it. This suggests that myosin light
chain phosphorylation is dependent on the 20-HETE receptor. ROCK1 protein
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levels were measured and Myh11-4a12 mice treated with either vehicle or AAA
had elevated levels compared to wild type animals. This indicates that ROCK1
expression is not dependent on the 20-HETE receptor. If the 20-HETE receptor
is not affecting ROCK expression, it may affect ROCK activity. Ex vivo
experiments were performed in wild type mice to assess the mechanism in which
20-HETE increases myogenic tone. The current report shows that 20-HETE
shifts the internal diameter curve downward, suggesting an increase in myogenic
tone. Co-administration of 20-HETE plus AAA or Rho-kinase inhibitor (Y-27632)
shift the internal diameter curve upward similar to control values. Finally, cotreatment of 20-HETE with AAA and Y-27632 had no further changes in
myogenic tone. This suggests that Rho-kinase activity is acting downstream of
the 20-HETE receptor to promote changes in the myogenic response.
The finding above is similar to that in the report by Randriamboavonjy et.
al. (2003). They determined that 20-HETE was capable of inducing contraction in
small coronary arteries. Furthermore, they showed that small coronary arteries
treated with 20-HETE had increased phosphorylation of MLC (Randriamboavonjy
et al., 2003). The 20-HETE-induced phosphorylation of MLC was prevented with
Y-27632 treatment. The findings from Randriamboavonjy study and the results
from the present study suggests 20-HETE, through its receptor, is capable of
promoting Rho-kinase activity, and allows for MLC phosphorylation, promoting
VSMC contraction.
Treatment of Myh11-4a12 mice with AAA was unable to reverse the
remodeling phenotype in these mice. Media thickness and cross-sectional area
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remained elevated after 12 days of AAA therapy. In addition, Myh11 protein
expression was also unaffected with AAA treatment. In this model of 20-HETE
overexpression, VSMCs are in the contractile phenotype rather than the
synthetic. This was shown when comparing expression to smooth musclespecific differentiation markers. Myh11-4a12 had elevated Myh11, Tagln and
Acta2 mRNA expression compared to wild types. If the VSMC were in a synthetic
state, there should have been a reduction in the VSMC differentiation markers
compared to WT mice (Frismantiene et al., 2018). The mouse model used in this
experiment was a constitutive overexpression of Cyp4a12. It is possible that the
proliferative phenotype occurred early in development and then switched to a
contractile phenotype once the mouse reached adulthood.
In other models of 20-HETE overexpression, the use of 20-HETE
antagonists was able to prevent the remodeling phenotype (Ding et al., 2013;
Garcia, et al., (2015b)). In these experimental models, 20-HETE was induced by
DHT and was treated with a 20-HETE antagonist at the same time.
Pharmacological antagonism of 20-HETE can prevent vascular remodeling in 20HETE-dependent models; however, 20-HETE antagonism may not be able to
reverse remodeling after it has been established. Further studies will have to be
performed to understand the mechanisms in which 20-HETE induces VSMC
proliferation.
Another finding in the present study was that Myh11-4a12 mice had
impairment in NO signaling. When assessing phosphorylation of eNOS at Serine
1177 in the aorta, Myh11-4a12 mice had lower phosphorylated eNOS levels
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compared to wild type. The change in phosphorylated eNOS levels was
attributed to a reduction in total eNOS expression in aorta. This observation was
also shown in a rat model with endothelial specific Cyp4a2 overexpression
(Inoue et al., 2009). The changes in phosphorylated eNOS expression in
mesenteric arteries were attributed to changes in eNOS activity. Regardless, the
reduction in eNOS phosphorylation will result in decreased NO bioavailability.
The differences in changes in eNOS phosphorylation may be due to differences
that can be observed in different vascular beds (Aird, 2007). Myh11-4a12 mice
treated with AAA had elevated phosphorylated eNOS expression in both aorta
and mesenteric arteries. Thus, changes in eNOS activation are due to 20-HETE
acting through its receptor.
The changes in eNOS phosphorylation were also accompanied by
changes in VASP phosphorylation. VASP is a protein within the smooth muscle
that is activated by PKG. Activation of PKG requires NO from the EC to diffuse to
the VSMC to activate soluble guanylyl cyclase and increase cGMP. Thus, it can
be used as a marker for NO signaling occurring within the VSMC (Oelze et al.,
2000). In aortas of Myh11-4a12 mice, there was a significant reduction of
phosphorylated VASP compared to wild type. However, 12-day AAA therapy was
not able to increase phosphorylated VASP in Myh11-4a12 mice. This result
implies that other mechanisms may be present to reduce NO bioavailability that
are unaffected by AAA treatment.
At baseline values, Myh11-4a12 had impaired acetylcholine-induced
relaxation that was restored when vessels were treated with sodium nitroprusside
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(NO donor). This gives evidence that Myh11-4a12 mice have impairments in NO
mediated vasodilation. One explanation that was shown in the present study was
that eNOS activation was reduced. Another action that may have occurred is the
increased production ROS. 20-HETE has been shown to increase ROS in both
endothelium and VSMCs (Guo et al., 2007; Lakhkar et al., 2016). The generation
of ROS can sequester NO away from the VSMC and prevent the activation of
PKG.
Within the EC and VSMC, 20-HETE has been documented to display
different mechanisms in ROS generation. 20-HETE was shown to increase
NADPH oxidase activity in pulmonary EC (Medhora et al., 2008); however, 20HETE in human umbilical vein EC and human microvascular EC display NADPH
oxidase-independent ROS generation (Guo et al., 2007). 20-HETE was also
shown to generate ROS in VSMC by promoting increased superoxide production
by the mitochondria (Lakhkar et al., 2016). The differences in cell-specific
mechanism of ROS generation may explain why increases in eNOS
phosphorylation after AAA was not accompanied by increased VASP
phosphorylation. It is possible that AAA was not able to ameliorate all the ROSgenerating effects of 20-HETE. Future studies will have to be performed in order
to assess the mechanism of ROS generation in Myh11-4a12 mice and whether
AAA is capable of changing ROS amounts.
This study provides evidence that 20-HETE, through its receptor, is
capable of increasing blood pressure and promoting changes in small artery
vascular activity. One limitation of this study is that it cannot conclude that 20-
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HETE is acting through GPR75 to promote smooth muscle contraction. There are
no current reports showing direct binding of AAA to GPR75; however, work is
being done to show that AAA binds to GPR75 (unpublished data). The relevance
of GPR75 can be assessed by using siRNA capable of downregulating GPR75
expression. In the report by Garcia and colleagues (2017), they used siRNA to
downregulate GPR75 expression in the vessels which promoted reductions in
blood pressure and improvement in vascular reactivity. Furthermore, they
showed that knock down of GPR75 reduced phosphorylation of the BKCa2+channel which inhibits the activity of the transporter (Garcia et al., 2017). Similar
approaches can be used to assess the relevance of GPR75 on Rho-kinase
activity. Furthermore, there are GPR75 global knockout and GPR75-flox mice
that are available to further dissect the mechanisms in which GPR75 is involved.
A second limitation of this study was that the mouse model used was a
constitutive overexpression of Cyp4a12. Due to this, it cannot be determined
whether 20-HETE is causing increases in blood pressure that promotes vascular
remodeling or if 20-HETE is causing remodeling followed by increases in blood
pressure. In one report, the investigators suggest that remodeling in vessels is
independent in changes of blood pressure. 20-HETE overproduction was
induced by DHT treatment and, in order to mitigate the increase in blood
pressure, reserpine was administered (Ding et al., 2013). Mice treated with both
DHT and reserpine experienced vascular remodeling without increases in blood
pressure. The utilization of an inducible model of Cyp4a12 expression in the
VSMC may be able to show 20-HETE’s contribution on blood pressure and
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vascular remodeling. There is a mouse line with cre-recombinase expression
targeted in the VSMC that is inducible with tamoxifen treatment (Wirth et al.,
2008). Similar experiments can be performed in which mice can be coadministered tamoxifen and AAA to determine if 20-HETE receptor antagonism
can prevent remodeling in resistant vessels with Cyp4a12 overexpression.
Furthermore, AAA can be administered after tamoxifen-induced Cyp4a12
expression to determine if 20-HETE receptor antagonism can reverse the
remodeling phenotype (Gilani et al., 2018). From these treatment groups, more
insight can be obtained with regards to 20-HETE receptor-mediated actions to
alter VSMC remodeling.
Future experiments can be done to determine if AAA can reverse vascular
remodeling. Twelve-day AAA treatment was not able to decrease RIA media
thickness and cross-sectional area. One reason for AAA’s inability to reverse
vascular remodeling is that the duration of treatment was too short to produce an
effect. Vascular remodeling is a complex process that involves the production of
new proteins to form a viable cell. These changes may take longer periods of
time to produce a measurable effect. In addition, the VSMC that are present may
take time to undergo apoptosis to reduce the number of cells within the vessel
wall. There may be several mechanisms by which 20-HETE receptor antagonism
can change signaling to inhibit VSMC proliferation.
Another explanation in which AAA was unable to reverse the vascular
remodeling phenotype may be due to 20-HETE promoting hypertrophy in
addition to or rather then proliferation. 20-HETE has been documented to
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promote hypertrophy in cardiomyocytes that contributes to heart failure in
experimental animals (El-Kadi and Zordoky, 2008; Zordoky et al., 2008). There
are no reports to suggest that 20-HETE can contribute to hypertrophy in resistant
vessels. It is possible that 20-HETE can promote hypertrophy due to its ability to
increase ACE expression and activity followed by increased Ang II (Cheng et al.,
2012; Garcia et al., 2016). Furthermore, 20-HETE has been documented to
activate mitogenic signaling that can also contribute to VSMC hypertrophy (Uddin
et al., 1998; Muthalif et al., 2001). Further experimentation can be performed to
assess 20-HETE action to promote hypertrophy and to determine if AAA is able
to prevent it.
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Perspective and Significance
Hypertension is a global burden of which approximately one fourth of the
world population is diagnosed. Hypertension is a risk factor for several diseases
including myocardial infarction, stroke, and renal failure. Although therapies are
present such as ACE inhibitors/ARBS, diuretics and beta-blockers to control
blood pressure there is a percentage of the population that do not respond to
these therapies. Thus, there is a need to identify novel mechanisms that can be
probed to improve blood pressure.
20-HETE has been extensively studied and consistently shows its role in
blood pressure regulation. Actions include: 1) endothelial dysfunction, 2) elevated
sodium reuptake; 3) VSMC contraction and proliferation. The multifaceted
actions of 20-HETE on blood pressure make it an ideal target for blood pressure
control. The use of pharmacological tools to either reduce the synthesis or inhibit
the action of 20-HETE have shown positive effects on blood pressure and
vascular function. What was not known until recently was how 20-HETE was able
to initiate its downstream effects in the cell. The work of Garcia and colleagues
(2017) was the first report to identify GPR75 as the receptor for 20-HETE.
Identification of a novel GPCR for 20-HETE make it an attractive target for
pharmacological manipulations. Future studies will be performed to fully
characterize the actions of 20-HETE on blood pressure and vascular function
through GPR75.
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